Study details
Enrolling now
Lovenox 30 mg Twice Daily (BID) Versus 40 mg Once Daily (QD)
Oregon Health and Science University
NCT IDNCT02342444ClinicalTrials.gov data as of Apr 2026
Phase
Phase 4
Target enrollment
606
Study length
about 11 years
Ages
15–100
Locations
1 site in OR
About this study
This trial is testing whether a lower dose of Lovenox, given twice daily, or a higher dose, given once daily, is better at preventing blood clots in people who are at risk. The goal is to see if one dose reduces the chance of blood clots compared to the other.
Based on ClinicalTrials.gov records.
What participants do
- 1.Receive Enoxaparin Sodium Injection 30 mg BID
- 2.Receive Enoxaparin Sodium Injection 40 mg QD
PhasePhase 4
DrugEnoxaparin Sodium Injection 30 mg BID
Routeinjection
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low5%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
Cardiovascular Agent [TC] (Antithrombins)
Drug routes
injection